Thall, Peter

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchImmune Cell Function and Interaction

Cited by 2,217

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research

Cited by 158

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.

Thall, P. F., Simon, R. M., & Estey, E. H. (1996) · Journal of Clinical Oncology

Statistical Methods in Clinical TrialsProbability and Statistical Research

Cited by 131

Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer

Wang, L., Rotnitzky, A., Lin, X., Millikan, R. E., & Thall, P. F. (2012) · Journal of the American Statistical Association

Statistical Methods in Clinical TrialsAdvanced Causal Inference Techniques

Cited by 108